^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) + Sulanda (surufatinib) (VEGFR inhibitor, FGFR1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
155P - Surufatinib plus toripalimab for 2L treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm phase 2 study
Published date:
12/02/2021
Excerpt:
In subgroups of PD-L1 positive pts, in cohort A (defined CPS ≥1), cohorts B and C (CPS ≥5), respectively, the confirmed ORR: 37.5% (15.20-64.57) in 16 pts, 38.5% (13.86-68.42) in 13 pts and 22.2% (2.81-60.01) in 9 pts; mPFS: 4.50 mo (2.60-7.59), 4.27 mo (1.25-5.72) and 5.32 mo (1.18-11.50), respectively....S + T exhibited promising efficacy and manageable toxicity in pts with previously treated advanced G/GEJ adenocarcinoma, ESCC and NEC, especially for PD-L1 positive pts.
Trial ID:
